Do you have any questions?
Don't hesitate to contact us. We are happy to answer your questions.
Meet us at EHA2024
Meet our medical team to find out more about our clinical program and CAR-T therapies on June 13-16, 2024 in Madrid, Spain
Meet us at EHA2024
Meet our medical team to find out more about our clinical program and CAR-T therapies on June 13-16, 2024 in Madrid, Spain
We are looking forward to your visit during EHA2024
We are excited to be present at the #EHA2024 Hybrid Congress, June 13-16 in Madrid, Spain. We look forward to welcoming you to our booth (D03), where you will be able to speak to our medical team about our clinical program and open trials. Check out this web page to see what we can discuss with you in Madrid.
#EHA2024 will take place at the IFEMA MADRID RECINTO FERIAL (Fairgrounds), Madrid, Spain. You will find us at the Miltenyi Biomedicine booth D03.
Exhibits area opening hours:
13 June, 9:00 a.m. – 5:00 p.m.
14-15 June, 9:00 a.m.- 4:30 p.m.
16 June, 9:00 a.m.-1:30 p.m.
See the detailed program of the EHA2024 Hybrid Congress
Check the #EHA2024 program hereLatest resources and news about Miltenyi Biomedicine presented at #EHA2024
DALY 2-EU trial –
now recruiting
Visit official trial page
Latest resources from Miltenyi Biomedicine
View recent posters, presentations and press releases
Tandem CD20-CD19-Directed Non-Cryopreserved CAR T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma - Interim Results from a Phase 2 Pivotal Study (DALY II USA)
Tandem Meetings – Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR | presentation slides
Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (zamto-cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma
ASH24 | presentation slides
Miltenyi Biomedicine will share positive interim results from DALY II USA at the American Society of Hematology (ASH) Annual Meeting
ASH 2024 | press release
Bispecific anti-CD20/19 CAR-T – zamtocabtagene autoleucel for relapsed/refractory DLCBL – interim analysis results of DALY-II-USA study
EHA2023 Hybrid Congress | poster information
Interim analysis of a Phase II study of administered fresh bispecific anti-CD20/anti-CD19 CAR T cell therapy zamtocabtagene autoleucel (zamto-cel) for relapsed/refractory (R/R) DLBCL (DALY II USA, NCT04792489)
Tandem Meetings of ASTCT and CIBMTR 2023 I presentation slides
PHASE I TRIAL OF MB-CART2019.1 IN PATIENTS WITH RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA
EHA 2022 | poster download
Characterization and T-Cell Repertoire of MB-CART2019.1 (Zamtocabtagene autoleucel) - Data from the Phase I Trial
ASH 2022 | presentation abstract
Healthcare Resource Utilization and Associated Costs of German Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
ASH 2022 | presentation abstract
Survival Patients Newly Diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL) - Real World Evidence from Germany
ASH 2022 | presentation abstract
